Top Story Today
The $1.9B Pill That Wants to Make Needles Extinct
Chiesi is paying $1.9 billion (a 40% premium) to acquire KalVista and its drug Ekterly, the only FDA-approved oral treatment for acute hereditary angioedema attacks. The drug generated $49.1 million in its first eight months and already captured nearly 20% of the on-demand market. The deal is part of an M&A frenzy driven by patent cliffs and pharma's appetite for rare disease assets with premium pricing power.
Why it matters: The deal underscores a broader pharma conviction that oral therapies will displace injectable standards of care in rare disease, and signals that approved, commercially proven assets in growing markets can still command massive premiums in 2026's red-hot M&A environment.
Read more →Deals & M&A
Teva Breaks a Decade of Silence With $700M Tourette Bet
After ten years of paying off debt and sitting out M&A, Teva dropped $700 million on Emalex Biosciences to grab ecopipam, the first new Tourette syndrome mechanism in over 30 years. The D1 receptor antagonist hit both primary and secondary endpoints in Phase 3 and could file for approval in late 2026. Teva shares jumped 6% on the news.
Read more →$2 Billion for a Drug That Hasn't Touched a Human
BeOne Medicines committed up to $2 billion for HH160, a preclinical trispecific antibody from Huahui Health that targets PD-1, CTLA-4, and VEGF-A simultaneously. The option structure limits upfront risk to $20 million while reserving rights to what could be the first approved trispecific. No trispecific antibody has reached market yet.
Read more →AstraZeneca Pays $25M to Destroy What It Can't Block
AstraZeneca exercised its option to license PTX-299, a preclinical EGFR degrader from Pinetree Therapeutics, in a deal worth over $500 million total. Instead of blocking the cancer protein, the drug destroys it entirely, potentially rescuing patients whose tumors mutated past osimertinib. The antibody-based approach targets cell-surface proteins that traditional small-molecule degraders can't reach.
Read more →Clinical & Regulatory
GSK's $700M Alzheimer's Bet Just Lost Twice
GSK and Alector killed their second neurodegeneration trial in six months after an interim analysis found nivisnebart unlikely to meet its primary endpoint. Combined with latozinemab's Phase 3 failure in frontotemporal dementia in October, the $700 million partnership has now produced zero approved drugs. The double miss raises serious doubts about whether boosting the brain's immune system can slow neurodegeneration.
Read more →A Patient Death Freezes a Novel Schizophrenia Trial
The FDA placed a clinical hold on Newron Pharmaceuticals' Phase 3 ENIGMA-TRS 2 trial after a patient died at a non-U.S. site. Evenamide targets glutamate (not dopamine) for treatment-resistant schizophrenia, making it one of the few truly novel mechanisms in the space. The hold affects only U.S. sites; international enrollment continues.
Read more →AstraZeneca's Two Cancer Drugs Face a Skeptical FDA Panel
An FDA advisory committee is reviewing camizestrant (for ESR1-mutant breast cancer) and Truqap (for PTEN-deficient prostate cancer) in a single session. Both posted statistically significant Phase 3 results, but FDA reviewers question whether either proved clinically meaningful benefit. The outcome will test how the agency evaluates biomarker-driven approvals going forward.
Read more →Funding & Financings
Avalyn's IPO Raised 50% More Than Planned
Avalyn Pharma priced its IPO at $18 per share (the top of range), raising $300 million instead of the roughly $200 million originally planned. The company is developing inhaled versions of existing lung fibrosis drugs that deliver 35x higher lung concentrations with a fraction of systemic side effects. With the IPO proceeds combined with existing cash, it has a runway to push two candidates toward Phase 3.
Read more →